Stocks
Johnson & Johnson Financial Statements (JNJ) |
||||||||||
| Johnson & Johnsonsmart-lab.ru | % | 2020 | 2021 | 2022 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 22.02.2021 | 17.02.2022 | 31.12.2022 | 16.02.2023 | 16.02.2024 | 23.10.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 82 584 | 78 740 | 94 943 | 79 990 | 85 159 | 88 772 | |||
| Operating Income, bln rub | 16 945 | 20 470 | 23 703 | 23 193 | 24 836 | 24 854 | ||||
| EBITDA, bln rub | ? | 24 176 | 27 860 | 21 939 | 30 163 | 32 322 | 32 129 | |||
| Net profit, bln rub | ? | 14 714 | 20 878 | 17 941 | 17 941 | 35 153 | 13 329 | |||
| OCF, bln rub | ? | 23 536 | 23 410 | 21 194 | 21 194 | 22 791 | 9 290 | |||
| CAPEX, bln rub | ? | 3 347 | 3 652 | 4 009 | 4 009 | 4 543 | 1 783 | |||
| FCF, bln rub | ? | 20 189 | 19 758 | 17 185 | 17 185 | 18 248 | 7 507 | |||
| Dividend payout, bln rub | 10 481 | 11 032 | 11 682 | 11 682 | 11 770 | 5 854 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 71.2% | 52.8% | 65.1% | 65.1% | 33.5% | 43.9% | ||||
| OPEX, bln rub | 34 424 | 34 395 | 40 151 | 33 181 | 35 197 | 38 374 | ||||
| Cost of production, bln rub | 28 427 | 23 402 | 31 089 | 24 596 | 26 553 | 26 946 | ||||
| R&D, bln rub | 12 340 | 14 277 | 15 386 | 14 135 | 15 085 | 16 886 | ||||
| Interest expenses, bln rub | 201.0 | 183.0 | 214.0 | 276.0 | 772.0 | 425.0 | ||||
| Assets, bln rub | 174 894 | 182 018 | 187 378 | 187 378 | 167 558 | 0.000 | ||||
| Net Assets, bln rub | ? | 63 278 | 74 023 | 76 804 | 76 804 | 68 774 | 71 538 | |||
| Debt, bln rub | 35 266 | 33 751 | 39 659 | 39 642 | 29 332 | 0.000 | ||||
| Cash, bln rub | 25 185 | 31 608 | 23 519 | 22 281 | 22 927 | 25 475 | ||||
| Net debt, bln rub | 10 081 | 2 143 | 16 140 | 17 361 | 6 405 | -25 475 | ||||
| Ordinary share price, rub | 157.4 | 171.1 | 176.7 | 176.7 | 156.7 | 150.2 | ||||
| Number of ordinary shares, mln | 2 633 | 2 629 | 2 632 | 2 614 | 2 534 | 2 428 | ||||
| Market cap, bln rub | 414 305 | 449 737 | 464 960 | 461 692 | 397 101 | 364 695 | ||||
| EV, bln rub | ? | 424 386 | 451 880 | 481 100 | 479 053 | 403 506 | 339 220 | |||
| Book value, bln rub | -26 517 | -7 615 | -16 752 | 2 268 | -1 959 | 71 538 | ||||
| EPS, rub | ? | 5.59 | 7.94 | 6.82 | 6.86 | 13.9 | 5.49 | |||
| FCF/share, rub | 7.67 | 7.52 | 6.53 | 6.58 | 7.20 | 3.09 | ||||
| BV/share, rub | -10.1 | -2.90 | -6.36 | 0.87 | -0.77 | 29.5 | ||||
| EBITDA margin, % | ? | 29.3% | 35.4% | 23.1% | 37.7% | 38.0% | 36.2% | |||
| Net margin, % | ? | 17.8% | 26.5% | 18.9% | 22.4% | 41.3% | 15.0% | |||
| FCF yield, % | ? | 4.87% | 4.39% | 3.70% | 3.72% | 4.60% | 2.06% | |||
| ROE, % | ? | 23.3% | 28.2% | 23.4% | 23.4% | 51.1% | 18.6% | |||
| ROA, % | ? | 8.41% | 11.5% | 9.57% | 9.57% | 21.0% | ||||
| P/E | ? | 28.2 | 21.5 | 25.9 | 25.7 | 11.3 | 27.4 | |||
| P/FCF | 20.5 | 22.8 | 27.1 | 26.9 | 21.8 | 48.6 | ||||
| P/S | ? | 5.02 | 5.71 | 4.90 | 5.77 | 4.66 | 4.11 | |||
| P/BV | ? | -15.6 | -59.1 | -27.8 | 203.6 | -202.7 | 5.10 | |||
| EV/EBITDA | ? | 17.6 | 16.2 | 21.9 | 15.9 | 12.5 | 10.6 | |||
| Debt/EBITDA | 0.42 | 0.08 | 0.74 | 0.58 | 0.20 | -0.79 | ||||
| R&D/CAPEX, % | 368.7% | 390.9% | 383.8% | 352.6% | 332.0% | 947.1% | ||||
| CAPEX/Revenue, % | 4.05% | 4.64% | 4.22% | 5.01% | 5.33% | 2.01% | ||||
| Johnson & Johnson shareholders | ||||||||||
